Annexon, Inc. (ANNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Anupam Rama
JPMorgan Chase & Co, Research Division

All right. Welcome, everyone, to the 44th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I am one of the senior biotech analysts here at JPMorgan. I’m joined by my squad, Joyce Zhou, Priyanka Grover and Rathi Pinhe. Our next presenting company is Annexon. And presenting on behalf of the company, we have CEO, Doug Love. Doug?

Douglas Love
CEO, President & Director

Great. Thank you, Anupam and JPMorgan. We’re delighted to be here for our 10th JPMorgan presentation. A decade into the journey, we’re more excited than ever to achieve our mission of delivering game-changing immunotherapies for patients suffering from devastating neuroinflammatory diseases. And so we’re going to dive right in. Hopefully, I’ll get my voice back. Great. There we go.

I’ll be making forward-looking statements and invite you to review our materials on file. All right. For those less familiar with Annexon, we’re a [ Bayera-based ] biotech company, leveraging our unique immunotherapy platform to unlock the next era of neuroinflammatory diseases to treat millions of patients suffering from these diseases. We’re led by 2 blockbuster registrational stage programs with the opportunity to treat more than — or to address more than $10 billion of market opportunities with these diseases and treat more than 10 million patients on an annualized basis.

Our lead program is in dry AMD with geographic atrophy, a devastating disease, a leading cause of blindness. And our lead program or our drug candidate, vonaprument, ANX007 has demonstrated outsized vision protection in this population. Our second drug candidate is tanruprubart targeting Guillain-Barre syndrome and